---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-000743"
form_type: "8-K"
ticker: "INSM"
cik: "0001104506"
company_name: "INSMED Inc"
filed_at: "2023-01-06T23:59:59+00:00"
generated_at: "2026-06-20T18:35:02.916998+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Insmed updates pipeline: ARIKAYCE 2023 rev guidance $285-300M; brensocatib CF data positive

## Summary
- ARIYACE global revenue 2022 up ~30% YoY; 2023 guidance $285-300M.
- Phase 2 brensocatib in CF showed dose-dependent NSP inhibition; 65 mg cohort not needed.
- Phase 3 ASPEN (bronchiectasis) blended blinded event rate 1.12-1.15 events/patient/year; enrollment on track for Q1 2023.
- Post-marketing ARISE trial had 15% treatment discontinuation rate, less than half of pivotal CONVERT.
- Early-stage pillars target musculoskeletal, CNS, ocular, rheumatologic; first IND expected H1 2023.

## SEC filing metadata
- accession: 0001140361-23-000743
- form_type: 8-K
- ticker: INSM
- cik: 0001104506
- company_name: INSMED Inc
- filed_at: 2023-01-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1104506/000114036123000743/0001140361-23-000743-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1104506/000114036123000743/brhc10046302_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-000743
- JSON: https://secwatch.observer/filing/0001140361-23-000743.json
- Plain text: https://secwatch.observer/filing/0001140361-23-000743.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.